StockData
MSLENasdaqPharmaceutical PreparationsFiscal year ends December 31

Satellos Bioscience Inc.

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 40-F on Mar 27, 2026
$6.44−0.02 (-0.31%)

Close on Oct 19, 2026

Market cap
–
P/E (TTM)
–
Dividend yield
–

About Satellos Bioscience

Pharmaceutical Preparations, SIC 2834

Satellos Bioscience Inc. is a Canada-based biotechnology corporation that focuses on the research and development of pharmaceutical products and therapeutic treatments. The company's activities primarily center on developing proprietary drug candidates and advancing licensed medical products through clinical trials, regulatory submissions, and potential commercialization. Operating as a single primary segment in drug research and development, its business initiatives and therapies are aimed at treating patients and serving stakeholders within the broader healthcare and biopharmaceutical industry.

The company maintains operational presence across Canada, the United States, and Australia. Its corporate headquarters and principal executive offices are situated in Toronto, Ontario, Canada, with additional administrative facilities and an agent for service located in Boston, Massachusetts, United States. Satellos conducts its clinical trial, developmental, and corporate activities under Canadian and U.S. regulatory oversight while managing international research commitments.

Summary of the business section of Satellos Bioscience's latest annual report, written by StockData.

Company profile

Company

Legal name
Satellos Bioscience Inc.
Headquarters
Markham, Ontario, Canada
Address
15 Allstate Parkway, Suite 600 L3R 5B4
Phone
(647) 660-1780
Industry
Pharmaceutical Preparations
Incorporated in
Z4
Fiscal year ends
December 31
Auditor
PricewaterhouseCoopers LLP, Toronto, Canada

Stock & identifiers

Ticker
MSLE
Exchange
Nasdaq
Shares outstanding
15M, Dec 31, 2025
Filer category
<br>Emerging growth company
Stock splits
1-for-12 reverse, Jan 30, 2026; 1-for-20 reverse, Aug 18, 2021
SEC CIK
1421642
CUSIP
80401L803
ISIN
US80401L8037
LEI
529900EN243BZ5QC9N39
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

No recent ownership filings by officers or directors

Satellos Bioscience's leadership is listed in its proxy statement (Form DEF 14A).

Corporate history

Events identified from SEC filings

DateEventDetails
Feb 5, 2026ListingRegistration of securities on an exchange (Form 8-A)
Sep 10, 2019Name changeName changed from ICO THERAPEUTICS INC to Satellos Bioscience Inc.